Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET-PA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Metlife (MET-PA) over the last 17 years, with Q3 2025 value amounting to $20.2 billion.

  • Metlife's Cash & Equivalents fell 703.88% to $20.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 billion, marking a year-over-year decrease of 703.88%. This contributed to the annual value of $20.1 billion for FY2024, which is 276.66% down from last year.
  • Latest data reveals that Metlife reported Cash & Equivalents of $20.2 billion as of Q3 2025, which was down 703.88% from $22.2 billion recorded in Q2 2025.
  • Metlife's 5-year Cash & Equivalents high stood at $25.0 billion for Q2 2021, and its period low was $1.3 billion during Q4 2022.
  • Over the past 5 years, Metlife's median Cash & Equivalents value was $20.2 billion (recorded in 2025), while the average stood at $18.4 billion.
  • As far as peak fluctuations go, Metlife's Cash & Equivalents crashed by 3421.72% in 2022, and later skyrocketed by 149992.25% in 2023.
  • Metlife's Cash & Equivalents (Quarter) stood at $2.0 billion in 2021, then crashed by 34.22% to $1.3 billion in 2022, then surged by 1499.92% to $20.6 billion in 2023, then dropped by 2.77% to $20.1 billion in 2024, then grew by 0.82% to $20.2 billion in 2025.
  • Its last three reported values are $20.2 billion in Q3 2025, $22.2 billion for Q2 2025, and $21.3 billion during Q1 2025.